These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8713775)

  • 21. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
    Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
    Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with highly purified porcine factor VIII in a patient with haemophilia A and a factor VIII inhibitor.
    Colvin BT; Ainsworth M; Buckley C
    Clin Lab Haematol; 1983; 5(1):55-9. PubMed ID: 6406130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of corticoids added to continued treatment with Factor VIII concentrates in the suppression of inhibitors in haemophilia A.
    Aznar JA; Jorquera JI; Peiró A; Garcia I
    Thromb Haemost; 1984 Apr; 51(2):217-21. PubMed ID: 6429884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E; Mauser-Bunschoten EP
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases.
    Huang YW; Saidi P; Philipp C
    Haemophilia; 2004 Nov; 10(6):713-21. PubMed ID: 15569166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors.
    Ciavarella N; Antoncecchi S; Ranieri P
    Br J Haematol; 1984 Dec; 58(4):641-8. PubMed ID: 6440588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia.
    Heneine W; Switzer WM; Soucie JM; Evatt BL; Shanmugam V; Rosales GV; Matthews A; Sandstrom P; Folks TM
    J Infect Dis; 2001 Feb; 183(4):648-52. PubMed ID: 11170992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. A French Multicentric Study.
    Fiks-Sigaud M; Bendelac L; Parquet A; Verroust F; Torchet MF; Berthier AM; Fressinaud E; Guerois C; Aillaud MF; Boneu B
    Vox Sang; 1993; 64(4):210-4. PubMed ID: 8517049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemophilia care in Europe: a survey of 19 countries.
    O'Mahony B; Noone D; Giangrande PL; Prihodova L
    Haemophilia; 2011 Jan; 17(1):35-40. PubMed ID: 20722746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Elimination of inhibitors in children with hemophilia A].
    Weissbach G; Domula M; Lenk H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):817-25. PubMed ID: 6083958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy.
    Hay CR; Laurian Y; Verroust F; Preston FE; Kernoff PB
    Blood; 1990 Sep; 76(5):882-6. PubMed ID: 2118396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of porcine factor VIII in the treatment of patients with acquired hemophilia.
    Morrison AE; Ludlam CA; Kessler C
    Blood; 1993 Mar; 81(6):1513-20. PubMed ID: 8453098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of porcine factor VIII in Japan.
    Yoshioka A; Shima M; Morichika S; Terada S; Fukui H
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):26-8. PubMed ID: 7939769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.